![]() |
市场调查报告书
商品编码
1830998
机器人辅助手术系统市场Robotic Assisted Surgery Systems Market |
机器人辅助手术系统市场预计将从 2022 年的 93.1 亿美元扩大到 2031 年的 253.8 亿美元,2025 年至 2031 年期间的复合年增长率预计为 14.9%。
市场洞察与分析师观点:机器人辅助手术系统市场涵盖各种先进的手术平台,这些平台结合了机器人技术、影像技术和导航技术,帮助外科医生以更高的精度和控制力进行微创手术。这些系统旨在提高手术能力,改善患者预后,并减少传统手术方法的创伤。机器人辅助手术系统的主要优势包括更高的灵活性、三维可视化和震颤抑制,使外科医生能够更精确、更灵活地执行复杂的手术。这些系统通常有助于进入具有挑战性的解剖区域,从而减少患者的创伤并加快康復时间。此外,在手术过程中加入机器人技术可以降低併发症的可能性,减少输血需求,最终获得更好的术后效果。
成长动力与挑战:越来越多的研究计画旨在探讨机器人辅助手术的优势和功能,预计在未来几年推动市场成长。 2022年9月,名古屋市立大学(NCU)医学研究生院的研究人员进行了一项研究,比较了机器人辅助、萤光透视引导和超音波引导下经皮肾镜取石术(PCNL)的肾臟通路。研究结果表明,创新机器人设备安全可靠且用户友好,可以减轻外科医生的培训需求,并使更多医院能够进行经皮肾镜取石术(PCNL)。这种利用人工智慧驱动的机器人技术的方法,或将为类似外科手术的自动化铺平道路,从而加快手术进程并降低併发症风险。
慢性病盛行率的上升以及人们对微创手术的日益青睐,进一步支撑了机器人辅助手术系统市场的成长。根据《印度教徒报》2022年8月报道,印度海德拉巴的阿波罗健康城已成功完成500多例机器人辅助妇科手术。 2022年11月,美敦力公司(Medtronic plc)的子公司印度美敦力私人有限公司(India Medtronic Private Limited)与德里的文卡特什瓦尔医院(Venkateshwar Hospital)宣布,在印度北部完成了首例使用Hugo机器人辅助手术(RAS)系统的泌尿外科手术。
相反,机器人手术系统的高昂成本对医疗机构的财务可行性和营运可持续性构成了挑战。虽然这些系统具有提高精准度、降低创伤性和缩短恢復时间等优势,但巨额的初始投资和持续的维护费用需要医疗机构进行周密的财务规划和资源分配。此外,手术人员需要接受专门的培训和认证才能操作这些系统,这也增加了营运成本,影响了将机器人手术纳入现有临床实践的整体可负担性和实用性。与机器人手术系统相关的财务负担可能会影响医疗保健报销模式和覆盖范围决策,因为使用机器人辅助进行的手术的报销率可能有所不同,从而影响采用这些技术的经济合理性。这造成了一个复杂的局面,医疗机构必须在机器人手术的临床效益和财务影响之间取得平衡,这可能会影响不同医疗保健系统的采用速度和范围。
策略洞察报告细分和范围:机器人辅助手术系统市场根据产品类型、应用和最终用户进行分类。就产品类型而言,市场分为系统、仪器和配件以及服务。根据应用,市场细分为妇科手术、心血管手术、神经外科、骨科手术、腹腔镜手术、泌尿科、一般外科等。根据最终用户,市场分为医院、门诊手术中心和其他最终用户。从地理上讲,机器人辅助手术系统市场分为北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、义大利、西班牙和欧洲其他地区)、亚太地区(中国、日本、印度、韩国、澳洲和亚太其他地区)、中东和非洲(阿联酋、沙乌地阿拉伯、南非和中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和其他地区)。
分部分析:就产品类型而言,手术机器人部分在 2022 年占据了机器人辅助手术系统市场相当大的收入份额。由于全球心血管和癌症相关疾病的发生率不断上升,预计对进行精确和准确手术的手术机器人的需求将会上升。美国癌症协会的《2023 年癌症统计数据》预测,美国将在 2023 年报告 190 万例新的癌症病例。根据澳洲健康与福利研究所 (AIHW) 2021 年的报告,2021 年澳洲估计有 150,800 例新的癌症病例。澳洲统计局在 2022 年 3 月报告称,估计约有 4.0% 的澳洲人(100 万人)在 2021 年患有心臟病。
根据应用,机器人辅助手术系统市场可分为妇科手术、心血管手术、神经外科、骨科手术、腹腔镜手术、泌尿科、一般外科及其他。预计神经外科领域在2022年至2030年期间的复合年增长率最高。手术机器人在一般外科手术中的日益普及及其相对于传统手术方法的优势,将对整个市场产生正面影响。此外,技术进步和机器人神经外科手术的成功经验预计将在未来几年推动机器人辅助手术系统市场的成长。根据SS Innovations Interventional Inc.的数据,2020年全球约有160万例机器人手术。
按最终用户划分,机器人辅助手术系统市场可细分为医院、门诊手术中心和其他最终用户。医院领域在2022年占据市场主导地位,预计2022年至2030年期间将达到高复合年增长率。医院领域的成长归因于各经济体医疗成本的上涨。医院利用最新的机器人辅助手术技术提供高品质的医疗服务。此外,医生和外科医生也青睐机器人辅助系统。根据《美国医学会杂誌》(JAMA) 网路发表的一篇论文报导,机器人辅助手术在外科手术总量中所占的比例已从2013年的1.8%显着上升至2019年的15.1%。
区域分析:从地理来看,机器人辅助手术系统市场分为北美、欧洲、亚太地区、中东和非洲以及南美和中美。北美是该市场成长的最大贡献者。该地区市场的成长得益于美国自动化手术器械的使用日益增多以及下一代医疗保健系统的采用。此外,美国外科医生和医疗专业人员相对于患者群体的短缺预计将使机器人辅助手术系统市场受益。糖尿病、癌症和心血管疾病等慢性疾病的盛行率不断上升,正在推动美国对机器人辅助手术系统的需求。
与传统手术相比,人们对微创手术的日益青睐推动了机器人辅助手术系统市场的发展。据美敦力公司称,2022年12月,Hugo在美国扩大了其机器人辅助手术 (RAS) 系统的临床试验,并招募了首位患者。此外,2022年,北卡罗来纳州达勒姆市杜克大学医院的一位医生实施了机器人辅助前列腺切除术。
预计 2022 年至 2030 年间,亚太地区机器人辅助手术系统市场将以最快的复合年增长率成长,这得益于患者人数的增加和先进自动化手术器械的普及。此外,现代医疗设施的扩张和公众对先进医疗技术益处的认识不断提高,预计将在未来支持该地区的市场成长。亚太各国政府正努力发展先进的医疗基础设施,吸引国际企业在该地区投资建立自动化器材开发设施。中国在亚太地区机器人辅助手术系统市场中占有最大份额,而印度预计将在 2022 年至 2030 年间实现最高的复合年增长率。中国手术机器人领域的公司利用特殊的审批途径加快了创新医疗产品的监管审批,缩短了产品上市时间。此外,中国正在涌现越来越多专门从事手术机器人的医疗科技公司。近期,健嘉机器人和Hurwa公司进军中国市场,携手专注于骨科手术机器人的本土公司天威科技(TINAVI)共同开发手术机器人解决方案。北京为天威机器人辅助的脊椎、髋关节和膝关节手术提供报销。
机器人辅助手术系统市场报告范围产业发展与未来机会:全球机器人辅助手术系统市场主要参与者采取的关键措施包括:
2023年10月,DePuy Synthes旗下的强生医疗科技公司(Johnson & Johnson MedTech)推出了VELYS机器人辅助解决方案,该解决方案已在德国、比利时和瑞士的全膝关节置换手术中得到应用。此次发布扩展了DePuy Synthes在其数位手术平台中的联网技术,以符合骨科机器人领域尚未满足的需求。
2022年11月,一家印度医疗科技公司与美国纳斯达克上市公司Avra Medical Robotics达成合作。 SS Innovations推出了SSI Mantra,这是第一款完全「印度製造」的手术机器人,它是一款高度先进的手术机器人系统,其功能和应用范围比其他系统更广泛。
2022 年 11 月,美国 FDA 批准了 Accelus 的 Remi 机器人导航系统软体更新,使进行腰椎固定的外科医生能够在机器人协助下放置椎弓根螺钉。 Accelus 是一家私人医疗技术公司,致力于推广微创手术 (MIS) 作为脊椎手术的护理标准。竞争格局与主要公司:机器人辅助手术系统市场的知名企业包括 Intuitive Surgical Inc.、Stryker Corporation、Johnson & Johnson Inc.、SRI International Inc.、Accuray Incorporated、Renishaw PLC、Medtronic PLC、Brainlab、Smith & Nephew PLC、Globus 和 Zimmer Biomet。这些公司专注于扩大其产品范围,以满足日益增长的全球需求。他们的国际影响力使他们能够服务广泛的客户群,从而提高他们的市场份额。
The market for robotic-assisted surgery systems is expected to expand from US$ 9.31 billion in 2022 to US$ 25.38 billion by 2031, with a projected CAGR of 14.9% during the period from 2025 to 2031.
Market Insights and Analyst View:The robotic-assisted surgery systems market includes a variety of advanced surgical platforms that combine robotics, imaging, and navigation technologies to aid surgeons in conducting minimally invasive procedures with enhanced precision and control. These systems aim to improve surgical capabilities, enhance patient outcomes, and reduce the invasiveness associated with traditional surgical methods. Key advantages of robotic-assisted surgery systems include improved dexterity, three-dimensional visualization, and tremor suppression, enabling surgeons to execute complex procedures with greater accuracy and flexibility. These systems often facilitate access to challenging anatomical regions, resulting in less trauma and quicker recovery times for patients. Furthermore, the incorporation of robotics in surgical procedures reduces the likelihood of complications and decreases the need for blood transfusions, ultimately leading to better post-operative results.
Growth Drivers and Challenges:The rising number of research initiatives investigating the advantages and functionalities of robot-assisted surgeries is expected to drive market growth in the upcoming years. In September 2022, researchers from the Graduate School of Medical Sciences at Nagoya City University (NCU) conducted a study comparing robotic-assisted, fluoroscopic-guided, and ultrasound-guided renal access for percutaneous nephrolithotomy. The results indicated the safety and user-friendliness of innovative robotic devices, which could alleviate the training demands on surgeons and enable more hospitals to perform PCNL procedures. This approach, utilizing AI-driven robotics, may pave the way for the automation of similar surgical interventions, thereby expediting processes and reducing complication risks.
The increase in chronic disease prevalence and the rising preference for minimally invasive surgeries further support the growth of the robotic-assisted surgical systems market. According to a report by The Hindu in August 2022, Apollo Health City in Hyderabad, India, has successfully completed over 500 robot-assisted gynecological surgeries. In November 2022, India Medtronic Private Limited, a subsidiary of Medtronic plc, and Venkateshwar Hospital in Delhi announced the completion of the first urological procedure in northern India using the Hugo robotic-assisted surgery (RAS) system.
Conversely, the high costs associated with robotic surgical systems pose challenges to the financial feasibility and operational sustainability of healthcare providers. While these systems provide benefits such as enhanced precision, reduced invasiveness, and shorter recovery times, the significant initial investment and ongoing maintenance expenses require careful financial planning and resource allocation for healthcare facilities. Additionally, the necessity for specialized training and certification for surgical staff to operate these systems adds to operational costs, affecting the overall affordability and practicality of incorporating robotic surgery into existing clinical practices. The financial burden linked to robotic surgical systems may influence healthcare reimbursement models and coverage decisions, as reimbursement rates for procedures performed with robotic assistance can vary, impacting the economic justification for adopting these technologies. This creates a complex scenario where healthcare facilities must balance the clinical benefits of robotic surgery against the financial implications, potentially affecting the rate and extent of adoption across various healthcare systems.
Strategic Insights
Report Segmentation and Scope:The robotic-assisted surgery systems market is categorized based on product type, application, and end user. In terms of product type, the market is divided into systems, instruments and accessories, and services. By application, the market is segmented into gynecological surgery, cardiovascular, neurosurgery, orthopedic surgery, laparoscopy, urology, general surgery, and others. Based on end user, the market is classified into hospitals, ambulatory surgery centers, and other end users. Geographically, the robotic-assisted surgery systems market is divided into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, South Africa, and the rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the rest of South & Central America).
Segmental Analysis:In terms of product type, the surgical robot segment accounted for a significant revenue share of the robotic-assisted surgery systems market in 2022. The demand for surgical robots to conduct precise and accurate procedures is expected to rise due to the increasing global incidence of cardiovascular and cancer-related disorders. The American Cancer Society's Cancer Statistics 2023 predicts that the US will report 1.9 million new cancer cases in 2023. According to the Australian Institute of Health and Welfare's (AIHW) 2021 report, there were an estimated 150,800 new cancer cases in Australia in 2021. The Australian Bureau of Statistics reported in March 2022 that approximately 4.0% of Australians, or 1.0 million people, were estimated to have heart disease in 2021.
By application, the robot-assisted surgical systems market is categorized into gynecological surgery, cardiovascular, neurosurgery, orthopedic surgery, laparoscopy, urology, general surgery, and others. The neurology sector is anticipated to experience the fastest CAGR from 2022 to 2030. The increasing adoption of surgical robots in general surgeries and the advantages they provide over traditional surgical methods are beneficial to the overall market. Additionally, advancements in technology and successful outcomes in robotic neurosurgery are expected to drive the growth of the robotic-assisted surgical systems market in the coming years. According to SS Innovations Interventional Inc., around 1.6 million robotic surgeries were performed globally in 2020.
By end user, the robot-assisted surgical systems market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospital segment led the market in 2022 and is projected to register a high CAGR from 2022 to 2030. The growth of the hospital segment is attributed to rising healthcare costs across various economies. Hospitals provide high-quality care by utilizing the latest robotic-assisted surgical technologies. Moreover, physicians and surgeons favor robot-assisted systems. The proportion of robot-assisted surgeries in total surgical procedures increased significantly from 1.8% in 2013 to 15.1% in 2019, as reported in a paper published in the JAMA network.
Regional Analysis:Geographically, the robotic-assisted surgery systems market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the largest contributor to the growth of this market. The market growth in this region is driven by the increasing use of automated surgical instruments and the adoption of next-generation healthcare systems in the US. Additionally, the shortage of surgeons and medical professionals in the US relative to the patient population is expected to benefit the market for robotic-assisted surgical systems. The rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions is driving demand for robotic-assisted surgical systems in the US.
The growing preference for minimally invasive procedures over traditional surgeries supports the robotic-assisted surgery systems market. In December 2022, Hugo expanded its clinical trials for its robotic-assisted surgery (RAS) systems in the US by enrolling their first patient, according to Medtronic plc. Furthermore, in 2022, a physician at Duke University Hospital in Durham, North Carolina, performed a robotic-assisted prostatectomy.
The Asia Pacific robotic-assisted surgical systems market is projected to grow at the fastest CAGR from 2022 to 2030, driven by the increasing patient population and the rising adoption of advanced automated surgical instruments. Additionally, the expansion of modern healthcare facilities and growing public awareness of the benefits of advanced medical technologies are expected to support market growth in this region in the future. Governments in Asia Pacific countries are making efforts to develop sophisticated healthcare infrastructure, attracting international companies to invest in the establishment of automated instrument development facilities in the region. China holds the largest share of the robotic-assisted surgical systems market in Asia Pacific, while India is expected to achieve the highest CAGR from 2022 to 2030. Companies in the surgical robotics sector in China have expedited their time to market by utilizing a special approval pathway that accelerates regulatory approval for innovative medical products. Moreover, a growing number of medtech firms specializing in surgical robotics are emerging in the country. Recently, JianJia Robots and Hurwa entered the Chinese market to develop surgical robotics solutions alongside TINAVI, a domestic company focused on orthopedic surgical robots. Beijing provides reimbursement for TINAVI robot-assisted surgeries for spinal, hip, and knee procedures.
Robotic Assisted Surgery Systems Market Report Scope
Industry Developments and Future Opportunities:Key initiatives undertaken by major players in the global robotic-assisted surgery systems market include:
In October 2023, Johnson & Johnson MedTech, a division of DePuy Synthes, launched the VELYS Robotic Assisted Solution, which has been utilized in total knee replacement surgeries in Germany, Belgium, and Switzerland. This launch expands DePuy Synthes' networked technologies within its Digital Surgery Platform to address unmet needs for orthopedic robots.
In November 2022, an Indian Medtech company partnered with Avra Medical Robotics, an American Nasdaq-listed firm. SS Innovations introduced the SSI Mantra, the first surgical robot entirely "Made in India," which is a highly advanced surgical robotic system with more features and applications than other systems available.
In November 2022, the FDA in the United States approved an update to Accelus's software for the Remi Robotic Navigation System, enabling surgeons performing lumbar spine fixation to place pedicle screws with robotic assistance. Accelus is a private medical technology company focused on promoting minimally invasive surgery (MIS) as the standard of care in spine procedures.
Competitive Landscape and Key Companies:Prominent players in the robotic-assisted surgery systems market include Intuitive Surgical Inc., Stryker Corporation, Johnson & Johnson Inc., SRI International Inc., Accuray Incorporated, Renishaw PLC, Medtronic PLC, Brainlab, Smith & Nephew PLC, Globus Medical, and Zimmer Biomet. These companies are focused on expanding their product offerings to meet the increasing global demand. Their international presence enables them to serve a broad customer base, thereby allowing them to enhance their market share.